Skip to main content
MedPathMedPath Home
Clinical Trials/2025-520801-12-00
2025-520801-12-00
Not yet recruiting
Phase 2

Inhibition of late sodium current (INa) to prevent coronary MICROvascular dysfunction in patients presenting with ST-Elevation myocardial infarction and multivessel disease: A multicenter, randomized, controlled and open label study (INaMICRON study)

Universita' Degli Studi Di Napoli Federico II3 sites in 1 country100 target enrollmentStarted: October 13, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Status
Not yet recruiting
Enrollment
100
Locations
3
Primary Endpoint
The relative difference in terms of IMR and/or angioIMR will be evaluated. IMR and/or angioIMR will be assessed both at the baseline (after successful coronary revascularization) and at the time of staged revascularization of the non-culprit stenosis (either at 5+/-2 days or within 6+/-2 weeks after pPCI).
OverviewEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

The aim of the present multicenter, randomized, controlled and open-label study is to evaluate the efficacy of late INa current inhibition to preserve coronary microcirculation after the acute myocardial infarction in patients presenting with STEMI and multivessel disease.

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age ≥ 18 years and < 80 years on day of signing informed consent
  • •Ability to provide written informed consent in a time window 0 to 1 day after successful pPCI.
  • •ST-Elevation Myocardial Infarction at the time of the index hospitalization.
  • •Successful pPCI (Thrombolysis In Myocardial Infarction [TIMI] flow 3 and residual coronary stenosis <30%).
  • •Presence of at least one remaining angiographically significant (% diameter stenosis > 50%) non-culprit stenosis treatable with PCI.
  • •Evidence of post-menopausal status or negative urinary or serum pregnancy test for child-bearing potential patients (definitions reported in section 10.9)..
  • •Agreement for child-bearing potential patients who are sexually active to use contraception (definitions reported in section 10.10)..

Exclusion Criteria

  • •Hemodynamically unstable patients
  • •Previous participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer.
  • •Previous myocardial infarction
  • •Previous coronary artery by-pass graft (CABG)
  • •Female patients with a positive pregnancy test at enrollment or prior to administration of study medication
  • •Female patients who are pregnant or breastfeeding or reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of Ranolazine
  • •Known hypersensitivity to the active principle (Ranolazine) or any of the excipients
  • •Chronic Kidney Disease Stage 4 or 5 (eGFR < 30 mL/min/1.73 m 2)
  • •Moderate to severe liver failure (Child Pugh B – C)
  • •Simultaneous intake of the following classes of drugs: strong CYP3A4 inhibitors (i.e. clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole); HIV protease inhibitors (i.e. saquinavir, indinavir, ritonavir); class Ia antiarrhythmic drugs (i.e. ajmaline, disopyramide, procainamide, quinidine ) and class III antiarrhythmic drugs except amiodarone (i.e. dofetilide, sotalol)

Outcomes

Primary Outcomes

The relative difference in terms of IMR and/or angioIMR will be evaluated. IMR and/or angioIMR will be assessed both at the baseline (after successful coronary revascularization) and at the time of staged revascularization of the non-culprit stenosis (either at 5+/-2 days or within 6+/-2 weeks after pPCI).

The relative difference in terms of IMR and/or angioIMR will be evaluated. IMR and/or angioIMR will be assessed both at the baseline (after successful coronary revascularization) and at the time of staged revascularization of the non-culprit stenosis (either at 5+/-2 days or within 6+/-2 weeks after pPCI).

Secondary Outcomes

  • The prevalence of residual CMD downstream to the culprit vessel in the two group of patients. Residual CMD will be defined as the finding of an IMRculprit or angioIMRculprit value > 25
  • The extent of the Infarct Size, as assessed by the CMR, in terms of grams (g) and percentage as compared with control group.
  • The prevalence of CMD downstream to the non-culprit vessel in the two group of patients (CMDnon-culprit). CMDnon-culprit will be defined as the finding of an IMRnon-culprit or angioIMRnon-culprit value > 25
  • The incidence of peri-procedural CMD after staged PCI of the non-culprit stenoses, defined as a 20% increase of IMRnon-culprit or angioIMRnon-culprit values assessed before and after elective PCI of the non-culprit vessel.
  • The difference between the two groups of patients, in terms of incidence of periprocedural Myocardial Infarction (PMI), eventually occurring during the staged procedure. PMI require to satisfy all the criteria of the fourth Universal Definition of Myocardial Infarction
  • The effects of INa current inhibition on endothelial function will be assessed at follow up as compared with control group. Endothelial function will be evaluated with the EndoPAT, measuring both the Endoscore and RHI
  • The incidence of MACE, defined as composite of death, myocardial infarction, or target-vessel revascularization at short (42+/-7 days) term follow-up.
  • Angina symptoms and quality of life will be assessed with SAQ7 and EuroQoL questionnaires and results compared between the two groups

Investigators

Sponsor Class
Educational Institution
Responsible Party
Principal Investigator
Principal Investigator

Luigi Di Serafino

Scientific

Universita' Degli Studi Di Napoli Federico II

Study Sites (3)

Loading locations...

Similar Trials

Recruiting
Phase 4
Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure
NCT07263035Lakeland Regional Health Systems, Inc.600
Active, not recruiting
Phase 3
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
2024-512837-34-00Teva Branded Pharmaceutical Products R&D LLC249
Recruiting
Phase 1
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC
2024-511956-42-00AstraZeneca AB44
Recruiting
Phase 3
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
NCT07265674J-Pharma Co., Ltd.480
Not yet recruiting
Not Applicable
SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
NCT07266519Philipps University Marburg25